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Abstract
 
Interleukin (IL)-10 and transforming growth factor (TGF)-
 
 
 
1 are suppressor cytokines that
frequently occur together during a regulatory T cell response. Here we used a one gene doxy-
cycline (Dox)-inducible plasmid encoding TGF-
 
 
 
1 to analyze this association and test its utility.
In initial studies, we showed that intranasal administration of this plasmid (along with Dox) led
to the appearance of TGF-
 
 
 
1–producing cells (in spleen and lamina propria) and the almost
concomitant appearance of IL-10–producing cells. Moreover, we showed that these cells exert
Dox-regulated suppression of the T helper cell (Th)1-mediated inflammation in trinitrobenzene
sulfonic acid colitis. In subsequent in vitro studies using retroviral TGF-
 
 
 
1 expression, we
established that IL-10 production by Th1 cells occurs after exposure to TGF-
 
 
 
1 from either an
endogenous or exogenous source. In addition, using a self-inactivating retrovirus luciferase
reporter construct we showed that TGF-
 
 
 
1 induces Smad4, which then binds to and activates
the IL-10 promoter. Furthermore, intranasal TGF-
 
 
 
1 plasmid administration ameliorates
bleomycin-induced fibrosis in wild-type but not IL-10–deficient mice, strongly suggesting that
the amelioration is IL-10 dependent and that IL-10 protects mice from TGF-
 
 
 
1–mediated
fibrosis. Taken together, these findings suggest that the induction of IL-10 by TGF-
 
 
 
1 is not
fortuitous, but instead fulfills important requirements of TGF-
 
 
 
1 function after its secretion by
regulatory T cells.
Key words: Th1 cells • trinitrobenzene sulfonic acid • ﬁbrosis • doxycycline • transcription
 
Introduction
 
In recent years, evidence has accumulated indicating that
naturally occurring regulatory cells producing TGF-
 
  
 
and/
or IL-10 can prevent or even reverse Th1 cell–mediated
inflammation (1–3). To take advantage of this finding for
the treatment of Th1-mediated mucosal inflammation, we
previously developed a method of creating “genetically
engineered” regulatory cells in vivo by direct introduction
of DNA encoding a regulatory cytokine, TGF-
 
 
 
1(4). In
this method the TGF-
 
 
 
1–encoding DNA (in the form of a
plasmid) is instilled into the nose and is either taken up by
migrating cells in the nasal mucosa or by cells at distant sites
exposed to plasmid that gains access to the circulation. In
either case, cells (both T cells and macrophages) producing
TGF-
 
 
 
1 can subsequently be found in the gastrointestinal
tract, where they either prevent colitis caused by intrarectal
administration of trinitrobenzene sulfonic acid (TNBS), or
treat such colitis after it is established (5, 6). One unexpected
finding arising from this method of inducing TGF-
 
 
 
1–
producing cells is that at sites of inflammation, T cells pro-
ducing large amounts of IL-10 are also found, and both
cytokines participate in the regulatory effect. This observation
is consonant with previous findings showing that TGF-
 
 
 
1
and IL-10 secretion tends to occur together at site of inflam-
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Abbreviations used in this paper:
 
 Dox, doxycycline; EMSA, electrophoretic
mobility shift assay; GFP, green fluorescent protein; LP, lamina propria;
SBE, Smad-binding element; TNBS, trinitrobenzene sulfonic acid.T
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mation (7–9). In this study, we sought to determine the
molecular and cellular basis of this association and to exam-
ine its clinical consequences.
For this purpose, we developed a one gene/integrated
doxycycline (Dox)-regulatable plasmid (10) that allows for
the rapid up-regulation and down-regulation of TGF-
 
 
 
1
by in vivo Dox administration. We observed that cosecre-
tion of IL-10 induced by plasmid is limited to T cells and
macrophages and that transduced CD4
 
  
 
T cells, reminis-
cent of naturally occurring suppressor T cells, produce large
amounts of IL-10 as a result of TGF-
 
 
 
1–induced Smad4-
mediated transcriptional activation of the IL-10 promoter.
Further, we found that TGF-
 
 
 
1 plasmid administration
somewhat paradoxically reverses bleomycin-induced pul-
monary fibrosis in wild-type mice and such reversal is IL-10
dependent because it does not occur in IL-10–deficient
mice in whom the plasmid does not induce IL-10. This
suggests that the association of TGF-
 
 
 
1 and IL-10 secre-
tion has advantages not only in relation to immunologic
suppression, but also in relation to the ability of TGF-
 
 
 
1 to
mediate fibrosis (11).
 
Materials and Methods
 
Mice.
 
Specific pathogen-free, 5–7-wk-old male SJL/J mice
and C57BL/6 mice were obtained from the National Cancer In-
stitute animal facility. IL-10–deficient mice were from Taconic.
 
Construction of pTet-On-TGF-
 
 
 
1.
 
Porcine-active TGF-
 
 
 
1
cDNA (12) was subcloned into pSuperlinker 1180 (Amersham
Biosciences) and then inserted into pRetro-On (CLONTECH
Laboratories, Inc.). rtTA-TGF-
 
 
 
1 cDNA mini–CMV-TRE
fragment was then inserted into the XhoI site of pCI (Promega)
that had two SV40 poly(A) in opposite directions (see Fig. 1 a).
 
Intranasal Administration of Plasmid DNA and Induction of TGF-
 
 
 
1.
 
We administered pTet-On-TGF-
 
 
 
1 intranasally (100 
 
 
 
g
plasmid in 20 
 
 
 
l PBS/mouse). Starting the next day, Dox was ad-
ministered for 5 d (500 
 
 
 
g in PBS, i.p./day/mouse).
 
Induction of TNBS Colitis and Culture of Lamina Propria (LP)
Mononuclear Cells.
 
We administered 2.5 mg TNBS (Sigma-
Aldrich) dissolved in 45–50% ethanol per rectum (4–7). After
mice were killed, we isolated LP mononuclear cells from colon
(13) and cultured them in 24-well plates (10
 
6 
 
cells/ml; Costar)
with the stimulation of coated anti-CD3
 
  
 
and soluble anti-CD28
(BD Biosciences) to assess IFN-
 
  
 
and
 
 
 
IL-10, and with the stimu-
lation of IFN-
 
  
 
and SAC (Calbiochem) to assess IL-12 produc-
tion. Cytokine productions in the supernatants were determined
by ELISA kits (Endogen; references 4 and 7). Culture in serum-
free medium supplemented with 1% nutridoma-SP (Roche Mo-
lecular Biochemicals) was performed for TGF-
 
 
 
1 ELISA without
acid treatment (Max TGF-
 
 
 
1 assay kit; Promega).
 
Bleomycin Treatment.
 
C57BL/6J mice were anesthetized by
i.p. injection of ketamine-HCl and xylazine-HCl. We induced
pulmonary fibrosis by intratracheal instillation of 0.15 U bleomy-
cin hydrochloride (Calbiochem) in 50 
 
 
 
l PBS using a 25-gauge
bulb-end needle.
 
Histological Examination.
 
The left lung of each mouse was first
perfused in situ, inflated, and then fixed with 10% buffered for-
malin. Paraffin-embedded sections were stained by the Masson’s
trichrome method.
 
Collagen Assay.
 
We harvested right lungs on days 14–21 after
bleomycin treatment and homogenized them in 10 mg tissue/10
ml 0.5 M acetic acid containing 1 mg pepsin and incubated them
for 24 h at 4
 
 
 
C with stirring. We determined lung collagen con-
tent by assaying total soluble collagen using the Sircol Collagen
Assay kit (Biocolor; references 14 and 15). Sircol dye reagent is
known to bind specifically to hydroxy proline, i.e., [Gly-X-Y]n
helical structures of Types I–V collagens. Acid soluble Type I col-
lagen supplied with kit was used to generate a standard curve.
 
TGF-
 
 
 
1 Retroviral Transfection of Primary T Cells.
 
We in-
serted active TGF-
 
 
 
1 cDNA into pBMN-IRES–green fluores-
cent protein (GFP; provided by G. Nolan, Stanford University,
Stanford, CA) and then transfected it into Phoenix-eco (Ameri-
can Type Culture Collection) to collect retroviral supernatants.
We stimulated SJL/J spleen CD4
 
  
 
T cells purified by CD4
 
  
 
T
cell–enriched columns (R&D Systems) with anti-CD3
 
 
 
/anti-
CD28 under the Th1 (rIL-12 and anti–IL-4 mAb) or Th2 (rIL-4
and anti–IL-12 mAb) conditions (15), or OVA-specific T cell
lines with 100 
 
 
 
g/ml OVA and APC. After 24 h stimulation, we
added retroviral supernatant in the presence of polybrene and
IL-2, and spun it at 1,000 
 
g
 
 for 90 min, followed by overnight in-
cubation at 32
 
 
 
C, and then resumed culture at 37
 
 
 
C (16). Every
12 d, Th1- and Th2-polarizing cells were restimulated. In some
experiments, 2 ng/ml rTGF-
 
 
 
1 (R&D Systems) was added every
3 d. We also transfected nonviral TGF-
 
 
 
1 plasmid into various
cell lines using LipofectAMINE2000 (Invitrogen) or the elec-
troporation method.
 
Intracellular Cytokine Staining.
 
On day 7 after stimulation of
 
 
 
CD3/CD28, CD4
 
  
 
T cells were stimulated with 50 ng/ml
PMA and 0.5 mM ionomycin for 6 h with monensin, and then
washed and fixed with 4% formaldehyde, and processed for cyto-
kine staining with PE–anti–IL-10 and/or APC–anti–IFN-
 
  
 
mAb
(BD Biosciences).
 
Preparation of Nuclear Protein Extracts and Electrophoretic Mobility
Shift Assays (EMSAs).
 
Jurkat cells stimulated with 5 ng/ml
TGF-
 
 
 
1 for 1 h were lysed in ice-cold hypotonic buffer (10 mM
Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA,
pH 8.0, 0.1 mM EGTA, 1 mM DTT, 0.6% Nonidet P-40, pro-
teinase inhibitor cocktail, sodium vanadate, and sodium fluoride).
The lysates were centrifuged to obtain nuclei pellets that were
then extracted with high salt nuclear extraction buffer (20 mM
Hepes-KOH, pH 7.9, 1.2 mM MgCl2, 420 mM NaCl, 25% glyc-
erol, 0.5 mM DTT, proteinase inhibitors, sodium vanadate, and
sodium fluoride) as described. Binding reactions containing 10 
 
 
 
g
nuclear extracts and 2 ng end-labeled oligonucleotides were per-
formed for 20 min at room temperature in 15 
 
 
 
l binding buffer
(20 mM Hepes, pH 7.9, 30 mM KCl, 4 mM MgCl 2, 0.1 mM
EDTA, 0.8 mM NaPi, 20% glycerol, 4 mM spermidine, and 3 mg
poly dI–dC; references 17 and 18). The probe sequences used for
EMSA are: Smad-binding element (SBE) variant in IL-10 pro-
moter, 5
 
 
 
-GGGAAGGTCCAGACATAATC-3
 
 
 
; specific com-
petitor of SBE variant, 5
 
 
 
-CAGGGTGTCCAGACGGCCAC-3
 
 
 
;
nonspecific competitor of SBE variant, 5
 
 
 
-GGGAAGTTTTA-
GACATAATC-3
 
 
 
; wild-type SBE sequence, 5
 
 
 
-CAGGGT-
GTCTAGACGGCCAC-3
 
 
 
; and specific competitor of wild-type
SBE, 5
 
 
 
-AGAATCGTCTAGACATATCT-3
 
 
 
. Antibody super-
shift assay using anti-Smad4 (Santa Cruz Biotechnology, Inc.) was
performed as previously described (18). Protein–DNA complexes
were resolved in 4% polyacrylamide gels in 0.5X TBE.
 
Preparation of Self-inactivated Retrovector for IL-10 Promoter Lu-
ciferase Assay in Primary T Cells.
 
A 1.37 kb murine IL-10 pro-
moter region was prepared by PCR using 5
 
 
 
Xho primer (265–
290) 5
 
 
 
-GCAGTTCTCGAGTCAATTCCATTC and NcoI
primer (1637–1614, GenBank M84340) 5
 
 
 
-AGCCAGCCATG-
GTGGAGCTCTCTT and ligated into pGL3-Basic vectorT
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(Promega). pBMN-IRES-EGFP was self-inactivated by convert-
ing the “TATA box” (AATAAA) in the 3
 
 
 
-LTR to the EcoRI
GAATTC sequence (19) using a site-directed mutagenesis kit
(Stratagene) with oligo 5
 
 
 
-CCCCGAGCTCGAATTCAGAGC-
CCAC-3
 
 
 
. IRES-EGFP fragment is replaced with two fragments:
IL-10 promoter luciferase-DSE-U
 
 
 
–deleted SV40 polyA, which
enables both polyadenylation and read through transcripts, and
CMV promoter EGFP. Smad-binding sequence (726–733 in
M84340) is mutated with the mutant SBE variant primer 5
 
 
 
-
GTCCCTACTGAAGGGAAGTTTTAGACATAATCAAAG-
GACTACC-3
 
 
 
. Primary CD4 cells under Th1 or Th2 develop-
ing conditions were retrovirally infected and harvested on day 6.
Cell lysates were analyzed for luciferase assays (Promega). All lu-
ciferase activities were normalized by the percentage of GFP ex-
pression by the flow cytometric analysis.
 
Results
 
Regulation of pTet-On-TGF-
 
 
 
1 In Vitro.
 
As shown in
Fig. 1 a, the regulatable “Tet-on” plasmid (termed pTet-
On-TGF-
 
 
 
1) consisted of two expression units: a TGF-
 
 
 
1
cDNA that contains a mutation that results in production
of “active” TGF-
 
 
 
1 (TGF-
 
 
 
1 not bound to latency-asso-
ciated protein) under a mini-CMV promoter (12) and a
CMV promoter-driven Tet-On transactivator (rtTA-
VP16) that binds a Tet-responsive element after interaction
with Dox (20, 21).
In initial studies, we transfected pTet-On-TGF-
 
 
 
1 into
Cos 7 cells and showed that there was no expression of
TGF-
 
 
 
1 in the absence of Dox. This is probably due to the
fact that the two expression units are arrayed in the plasmid
in opposite orientation so as to reciprocally block back-
ground transcription (22). In addition, as shown in Fig. 1 b,
we observed that the transduced cells produce large
amounts of TGF-
 
 
 
1 (2,600 pg/ml) in the presence of Dox,
whereas cells transduced with a conventional unregulatable
TGF-
 
 
 
1 expression plasmid (pCI-TGF-
 
 
 
1) secreted only
moderate amounts of TGF-
 
 
 
1 (890 pg/ml).
 
Regulation of pTet-On-TGF-
 
 
 
1 In Vivo and Its Relation to
IL-10 Secretion.
 
In the next series of studies, we examined
the in vivo expression and regulatability of TGF-
 
 
 
1 de-
rived from pTet-On-TGF- 1 and its relation to IL-10 se-
cretion. As shown in Fig. 1 c, we showed that after intra-
nasal pTet-On-TGF- 1 administration accompanied by Dox
coadministration, there was the rapid appearance of spleen
cells secreting high amounts of TGF- 1 and the rapid dis-
appearance of these cells after cessation of Dox administra-
tion. Perhaps more remarkably, we observed that the
emergence of these TGF- 1–secreting cells was accompa-
nied by the appearance of IL-10–producing cells, which
then persisted after TGF- 1 secretion declined. These re-
sults clearly show that TGF- 1 secretion rapidly induces
IL-10 secretion in vivo and that once such secretion is
turned on it is not rapidly down-regulated as is the TGF-
 1 secretion (which is under the control of a doxy-regu-
lated promoter).
In a further study we investigated the ability of the Tet-
On-TGF- 1 plasmid to affect an inflammatory state, ex-
emplified by the Th1-type colitis induced by TNBS (4–7).
Four groups of mice were studied: those receiving pTet-
On-TGF- 1 with or without Dox and those receiving
control plasmid (pTet-On-mock) also with or without
Dox. As shown in Fig. 2 a, using body weight as an indi-
cator of colitis, it was clear that the group that received
pTet-On-TGF- 1 (i.n.) and Dox (i.p.) was protected
from developing colitis, whereas the group receiving the
plasmid in the absence of Dox (or those mice receiving
pTet-ON-mock again with and without Dox) developed
colitis. In addition, although LP cells from all three groups
developing colitis produced large amounts of IL-12 and
IFN-  and small amounts of TGF- 1, LP cells from mice
prevented from developing colitis produced small amounts
of IL-12 and IFN-  and very large amounts of TGF- 1
(Fig. 2 b). Of interest, the latter was much greater than
that produced by cells taken from mice without inflamma-
Figure 1. Active TGF-  expression in vitro and in
vivo by pTet-On-TGF- 1. (a) Schematic map of the
pTet-On-TGF- 1 construct. TRE, Tet-responsive
element; rtTA, reverse tetracycline-controlled trans-
activator. (b) In vitro production of active TGF- 1 by
Cos 7 cells transfected with pTet-On-TGF- 1 exhibited
background TGF- 1 production in the absence of
Dox and induced much greater amount of TGF- 1
than pCI-TGF- 1. (c) In vivo expression of active
TGF- 1 and IL-10 in SJL/J mouse spleen cells after intra-
nasal  administration of pTet-On-TGF- 1 plasmid.
Spleen cells from mice (n   3) killed on the indicated
days were cultured with anti-CD3/anti-CD28 in the
absence of Dox and culture supernatants were assayed
for active TGF- 1 and IL-10 by ELISA. Because Dox
was not added to the splenocyte cultures, TGF- 1/IL-10
production measured reflect the capacity of cells to
produce these cytokines in vivo. TGF- 1 and IL-10
production was rapidly induced by Dox in mice ad-
ministered pTet-On-TGF- . In addition, TGF- 1 but
not IL-10 production rapidly declined after cessation
of Dox.T
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tion, reflecting the activation of the CMV promoter in an
inflammatory milieu. In addition, LP cells from this group,
but not those from the groups in which the plasmid was
not accompanied by Dox administration, produced large
amounts of IL-10. Thus, it was obvious that such IL-10
secretion was due to plasmid-induced TGF- 1 and not
simply to the presence of a Th1 inflammation. In further
studies not shown, we found that intranasal administration
of pTet-On-TGF- 1 also reversed TNBS colitis after in-
flammation was established, but only in the presence of
concomitant Dox administration.
Cell Types Producing IL-10 in Response to TGF- 1.
Next, we defined the cell types capable of producing IL-10
in response to exposure to TGF- 1. Here we first trans-
fected various murine cell lines with pCI-TGF- 1 under
optimal conditions or, in the case of CD4  T cells that ex-
hibit low transfection efficiency, we infected the cells with a
retrovirus encoding TGF- 1 (see below). We then deter-
mined IL-10 production in the modified cells. As shown in
Table I, a Th1 CD4  cell line (OVA-3), i.e., a T cell line
maintained by repeated OVA plus APC stimulation for  6
wk, and two macrophage cell lines (RAW264 and MH-S)
secreted substantial amounts of IL-10 after transfection (or
infection). In contrast, a thymus-derived T cell (EL-4) as
well as epithelial, squamous, and fibroblast cell lines from
lung and other tissues did not produce IL-10 after transfec-
tion (although they did produce TGF- 1). These studies
indicate that only certain types of hematopoietic cells are ca-
pable of IL-10 secretion as a result of exposure to TGF- 1.
IL-10 Production by Polarized Th1 Cell Populations in Re-
sponse to Both Endogenous and Exogenous TGF- 1. Next,
we addressed the question of whether the production of
IL-10 in a Th1 milieu could arise from the Th1 cells them-
selves. To this end, we transduced naive CD4  T cells
stimulated with anti-CD3/anti-CD28 with a bicistronic
retroviral vector expressing both TGF-  and GFP (termed
pBMN-TGF- 1 or retro-TGF- 1) under Th1 priming
conditions (IL-12 and anti–IL-4) or Th2 priming condi-
tions (IL-4 and anti–IL-12; reference 16). This allowed us
to distinguish infected cells (GFP , TGF- 1–producing
cells) from uninfected cells (GFP , TGF- 1–nonproducing
cells). As shown in Fig. 3 a, although developing CD4 
Th1 cells infected with control retrovirus (pBMN-mock or
retro-mock, i.e., retrovirus encoding only GFP) did not
Figure 2. Effect of intranasal pTet-On-TGF- 1 admin-
istration on TNBS-induced colitis. (a) Weight changes of
mice groups administered intrarectal TNBS and intranasal
pTet-On-TGF-   or pTet-On-mock (control plasmid)
with or without Dox (i.p.) Each group, n   10. (b) LP
cells from mice 5 d after TNBS colitis induction were
stimulated and cultured for ELISA assays of TGF- 1, IFN- ,
IL-10, and IL-12. As shown, LP cells from mice administered
Dox plus pTet-On-TGF- 1 produced large amounts of
TGF- 1 and IL-10 and exhibited suppressed IL-12 and
IFN-  production. Data shown is representative of three
independent experiments.T
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produce IL-10, similar cells infected with retro-TGF- 1
(retrovirus encoding both TGF- 1 and GFP) produced IL-10
whether or not they were GFP . On the other hand, as
shown in Fig. 3 b, developing Th2 cells exhibited IL-10
production when infected with either retrovirus regardless
of GFP positivity. These studies show quite clearly that
Th1 cells produce IL-10 either when they produce TGF-
 1 themselves or are exposed to TGF- 1 produced by
other cells.
In complementary studies, we measured the secretion of
IL-10 by naive cell populations infected with retro-mock
or retro-TGF- 1 and then subjected them to two rounds
of stimulation under either Th1 and Th2 conditions. As
shown in Fig. 3 c, in this case, cells stimulated under Th1
conditions again required infection with retro-TGF- 1 to
produce IL-10 and cells stimulated under Th2 conditions
produced (even higher levels of) IL-10 when infected with
either retro-TGF- 1 or retro-mock. In addition, IL-10
production was increased in both Th1 and Th2 cells after
the second round of stimulation. Finally, we noted that
Th1 cells infected with retro-mock could produce IL-10
with repeated addition of rTGF- 1 to the culture, but
only after the second round of stimulation. These studies
show that repeated stimulation of Th1 cells in the presence
of TGF- 1 (from retro-TGF- 1 or soluble rTGF- 1)
leads to Th1 cells capable of IL-10 production. In addition,
they suggest that exogenous TGF- 1 is a less efficient
means of inducing IL-10 than endogenous TGF- 1. Par-
enthetically, as shown in Fig. 3 d, repeated stimulation of
Th1 cells exposed to TGF- 1 become dual producers of
IFN-  and IL-10.
The Molecular Basis of TGF- 1 Induction of IL-10. On
the assumption that TGF- 1 induction of IL-10 observed
above could be related to TGF- 1 signaling via Smad acti-
vation of the IL-10 promoter, we searched the murine
IL-10 promoter region for an SBE (17, 18, 23, 24). Indeed,
we found an “SBE variant” site GTCCAGAC at  901 that
closely resembled the consensus SBE, GTCTAGAC, and
contained overlapping CAGA sequences (termed a CAGA
box; reference 25). In additional studies of whether this se-
quence actually binds to Smad proteins, we performed an
EMSA using nuclear extracts of TGF- 1–stimulated Jurkat
T cells and radiolabeled oligo with the SBE variant se-
quence. As shown in Fig. 4 a, we found that the nuclear ex-
tracts contained proteins that bound to the variant sequence
and that such binding was blocked by an unlabeled compet-
itor sequence, but not by a mutated variant sequence. Fur-
thermore, we showed that the addition of anti-Smad4 to
the mixture containing the extract plus variant sequence
causes a supershift. Thus, activated Smad4 does in fact bind
to an SBE variant sequence in the IL-10 promoter.
To assess whether the IL-10 promoter not only binds
Smad but also responds to Smad signaling, we constructed
self-inactivating retroviral reporter vectors that express lu-
ciferase under the control of the IL-10 promoter rather
than the retroviral promoter (19, 26). These included a
vector containing an IL-10 promoter with a mutated SBE
variant. The retroviruses also expressed GFP, which al-
Table I. Induction of IL-10 in T Cells and Macrophages by TGF- 1–expressing Constructs
TGF-  1 (pg/ml)b IL-10 (pg/ml)
Cell linea Plasmid/retrovirus mock TGF-  mock TGF- 
T cell
OVA-3 T cell clone regional LN  30 327  25 1,620
EL-4 (anti-CD3/anti-CD28) thymus 184 353  25  25
Macrophage
RAW264 (LPS 0.5  g) M  214 924 181 930
MH-S (LPS 0.5  g) alveolar M  119 636  25 161
Epithelial
CMT93 colon epithelial 440 1,270  25  25
C10 lung epithelial  30 468 44  25
E10 lung epithelial  30 1,028  25  25
LA-4 lung epithelial Ca  30 128  25  25
KLN205 lung squamous 88 552 48  25
Fibroblast
MLg lung fibroblast  30 268  25  25
3T3 embryo fibroblast 128 1,430  25  25
The value obtained for each cell line is the mean value from three independent experiments.
aMouse cell lines were transfected with pCI-TGF- 1 plasmid using TransfectAMINE 2000 or by electroporation (EL-4). The OVA-3 T cell clone
was infected with a retrovirus of pBMN-TGF- 1-GFP.
bTGF- 1 ELISA was performed after acid treatment.T
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lowed assessment of infection efficiency of the retrovirus
and normalization. We then coinfected polarized Th1 and
Th2 cells with these retroviruses as well as with retroviruses
expressing either pBMN-TGF- 1 or pBMN-mock (in
which the GFP cassette has been deleted) and monitored
TGF- 1 production by the coinfected cells by ELISA. As
shown in Fig. 4 b, in Th1 cells, the wild-type IL-10 pro-
moter gene generated a strong luciferase signal in cells ex-
Figure 3. Production of IL-10
by Th1 cells infected with a TGF-
 1–expressing retrovirus. (a) Sche-
matic map of the retroviruses used.
(b) Intracellular IL-10 staining of
developing Th1 and Th2 cells
on day 6 after stimulation with
 CD3/CD28 with retroviral
infection by retro-TGF- 1-GFP
or retro-mock-GFP. IL-10 is
produced by both GFP   and
GFP  Th1 developing cells. Th2
cells produce IL-10 in the absence
of retro-TGF- 1-GFP infection.
(c) Secretion of IL-10 by CD4  T
cells infected with retro-TGF- 1-
GFP or retro-mock-GFP under
Th1 or Th2 priming conditions.
IL-10 production by cells infected
with retro-mock-GFP under Th1
condition with the addition of
rTGF- 1 was also studied. Retro-
TGF- 1–infected Th1 and Th2
cells produced more amounts of
IL-10 after the second stimulation,
however, although Th2 cells
produce IL-10 with the infection
of retro-mock, Th1 cells only do
so with the addition of rTGF- 1
or infection of retro-TGF- 1.
(d) Intracellular staining of IL-10
and IFN-  of Th1 cells after the
third round stimulation with
 CD3/CD28.
Figure 4. TGF- 1 activates IL-10
promoter transcription through
Smad4 in Th1 cells. (a) EMSA shows
that TGF- 1–induced nuclear extracts
exhibited binding activity to an SBE
variant oligo as well as native SBE
oligo. Anti-Smad4 antibody causes
supershift of the complex with the
SBE variant. (b) Schematic map of
self-inactivating pBMN-IL-10 lu-
ciferase reporter genes. (c) Luciferase
activity of IL-10 promoter was assayed
by infection with self-inactivating
retroviruses. Retrovirally expressed
TGF- 1 induces IL-10 promoter
activity in developing Th1 cells signal-
ing through SBE variant sequence,
but TGF- 1 is not required for acti-
vation of IL-10 promoter in devel-
oping Th2 cells.T
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pressing TGF- 1, whereas only a basal luciferase signal was
seen in cells with a mutated promoter. In contrast, in Th2
cells both the wild-type and mutated promoters were acti-
vated even in the absence of TGF- 1, indicating that IL-10
production is independent of TGF- 1-Smad signaling and
the transcriptional activation of IL-10 in Th2 cells does not
depend on the SBE variant sequence. These data provide
strong support for the view that TGF- 1 induces IL-10 via
transcriptional activation of the IL-10 promoter by acti-
vated Smad protein(s).
IL-10 Induced by Intranasal pTet-On-TGF- 1 Ameliorates
Bleomycin-induced Lung Fibrosis. The above evidence that
TGF- 1 production by T cells is associated with IL-10 in-
duction whereas such production in other non–T cells is
not, implied that the IL-10 production has effects on TGF- 
function during lymphoid cell interactions. We investi-
gated this possibility in relation to the induction of fibrosis,
a notorious side effect of TGF- 1 secretion (27–29). In
particular, we examined the effect of intranasal administra-
tion of pTet-On-TGF- 1 on bleomycin-induced fibrosis
in the lung, as quantified by Masson trichrome staining and
by collagen content. In control studies shown in Fig. 5, a
and b, we established that intranasal administration of either
pTet-mock or pTet-On-TGF- 1 did not induce fibrotic
changes. Then, as shown in Fig. 5, c and d, we established
that although bleomycin induced severe fibrosis when ac-
companied by the administration of pTet-mock, such fi-
brosis was significantly decreased when accompanied by
the administration of pTet-On-TGF- 1 plus Dox. Thus,
rather than itself inducing fibrosis, pTet-On-TGF- 1 in-
hibited fibrosis induced by bleomycin. Finally, as shown in
Fig. 5, e and f, the same study performed in IL-10–defi-
cient mice showed that in the absence of IL-10 induction,
the protective effect of the pTet-On-TGF- 1 plasmid was
lost and in this case bleomycin did induce fibrosis in mice
administered pTet-On TGF- 1 plus Dox. As shown in
Fig. 5 g, confirmation of this result was obtained by mea-
surement of the collagen content of the lungs studied under
the various conditions outlined above. This provides strong
evidence that the ability of pTet-On-TGF- 1 to inhibit
bleomycin-induced fibrosis is in fact due to its ability to in-
duce IL-10.
Discussion
In these studies, using a regulatable TGF- 1–expressing
plasmid (termed pTet-On-TGF- 1), we show that in vivo
TGF- 1 secretion rapidly induces IL-10 secretion and that
such induction occurs in Th1 cells via Smad4 binding to
and activation of the IL-10 promoter. The close association
of these two major “regulatory” cytokines thus revealed
mirrors their association during suppressor function occur-
ring in association with Th1-mediated inflammation (30).
Powrie et al. (31) for instance, has shown that in the SCID-
transfer model of colitis, the regulatory effect of the sub-
population of cells in the memory CD45RBlow cells is ab-
rogated by administration of anti–TGF- 1 or anti–IL-10R
and that such cells either produce or induce TGF- 1 and/
or IL-10 (8, 9). In addition, we have shown that the regu-
lation of TNBS colitis by feeding TNP-substituted proteins
Figure 5. Amelioration of bleomycin-induced lung fibrosis by intranasal administration of pTet-On-TGF- 1. (a–f) Masson’s trichrome stain of lung
sections from bleomycin-treated and control mice including B6 wild-type (a–d) and IL-10 KO (e and f). pTet-On-mock and Dox-treated mouse lungs
(a, c, and e) and pTet-On-TGF- 1 and Dox-treated mouse lungs (b, d, and f) without (a and b) or with bleomycin induction (c–f). Representative pictures
are shown.  400. (g) Collagen content (n   9 in each group) in the bleomycin-induced fibrotic lungs evaluated by Sircol dye assay. Administration of
pTet-On-TGF-  effectively reduces fibrotic changes in both assays.T
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requires both TGF- 1 and IL-10 (7). Finally, we and oth-
ers have also shown that both “self–MHC-reactive” and
CD4  CD25  regulatory T cells produce both TGF- 1
and IL-10 upon appropriate stimulation (32–34).
The fact that TGF-   induces IL-10 as shown here
whereas IL-10 does not induce TGF- 1 strongly suggests
that IL-10 facilitates TGF- 1 regulatory function and not
the other way around (4, 7). One way such facilitation
could occur is through IL-10 enhancement of TGF- 1 sig-
naling. This possibility is supported by Cottrez and Groux
(35) who showed that IL-10 maintains TGF- 1RII expres-
sion on activated cells that would otherwise down-regulate
this receptor. In addition, it is known that Th1 cytokines
such as IFN-  and TNF-  up-regulate Smad7, a cytosolic
intermediate that inhibits TGF- 1 signaling via other
Smads (36, 37) and it is thus possible (but not yet proven)
that IL-10 inhibits such Smad7 up-regulation.
Another way that IL-10 could facilitate TGF- 1 regula-
tory activity is via an ability to sustain TGF- 1 secretion or
allow the expansion of TGF- 1–producing cells. Support
for this possibility comes from our recent observation that
TGF- 1–mediated regulatory function induced by feeding
antigen is not only abrogated by anti–TGF- 1 administra-
tion, but also by anti–IL-10 administration and that in fact
no TGF- 1 production occurs in such fed mice given
anti–IL-10 (7). Further work showed that the effect of
anti–IL-10 does not occur during the induction of TGF-
 1–producing cells (in the absence of Th1 cytokines), but
rather during the expansion of these cells (in the presence
of Th1 cytokines) when they might be expected to un-
dergo antigen-induced proliferation. These findings suggest
that either nascent TGF- 1–producing regulatory cells un-
dergo a turn-off of TGF- 1 production or fail to expand in
the face of Th1 cytokine production. Thus, it is reasonable
to suggest that IL-10 sustains TGF- 1 secretion directly by
counteracting the negative effect of Th1 cytokines on
TGF- 1 production or indirectly by down-regulating Th1
cytokine secretion. Both of these possibilities would ex-
plain the observation that mice expressing large amount of
IL-10 in epithelial cells as a result of an epithelial cell–spe-
cific IL-10 transgene exhibit an increase in TGF- 1 ex-
pression in the underlying LP (38). In addition, it accords
with the observation that T cell TGF- 1 secretion is not
seen during the Th1 response observed when TNBS colitis
is induced in SJL/J mice but is seen during the Th2 re-
sponse observed in the oxazolone colitis occurring in the
same strain (39). Taken together, these considerations
strongly suggest that TGF- 1 induction of IL-10 fulfills an
important requirement of regulatory T cell activity.
Although TGF- 1 and IL-10 as discussed above might
be interdependent during a regulatory response, it is possible
that their cosecretion also occurs because these cytokines
regulate different aspects of an inflammatory response and
are thus synergistic in their activity. This is supported by the
fact that in Th1-driven inflammation, although TGF- 1
regulates Th1 cells via its ability to down-regulate T-bet and
the IL-12R 2 chain (4, 40), IL-10 regulates via down-reg-
ulation of IL-12 and TNF-  secretion (4, 41, 42). Thus, the
regulatory activity of TGF- 1 and IL-10 acting together is
greater than either of these cytokines acting alone.
An important and interesting aspect of TGF- 1 induc-
tion of IL-10 relates to our observation that such induction
affects Th1 cells rather than Th2 cells (which exhibit IL-10
secretion in the absence of TGF- 1 and which are not in-
duced to produce additional IL-10 by the presence of TGF- ).
In a previous study by Blokzijl et al. (43) using the HT-2
cell line (a cell line that produces IL-10 but not IL-4 or
IL-5), it was found that TGF- 1–induced Smad3 interacts
directly with GATA-3 and the complex formed acts coop-
eratively to up-regulate IL-10 expression (by  1.8-fold) in
a Smad3- and GATA-3–dependent fashion. This result is
somewhat at odds with our data showing that IL-10 pro-
duction by freshly prepared Th2 cells is not enhanced by
TGF- 1 and is best explained by differences in the cells be-
ing studied. Blokzijl et al. (43) used an established cell line
of uncertain lineage, whereas we used a freshly stimulated
Th2 cell line. Finally, we observed that CD4  T cells ex-
posed to TGF- 1 during induction of T cell differentiation
produced much lower amounts of IL-10 when stimulated
under neutral priming conditions than under Th1 priming
conditions (unpublished data). This indicates that activation
of the IL-10 promoter is not solely dependent on TGF- 1,
but also involves other unknown factors induced during the
differentiation of Th1 cells.
In addition to its role as a suppressor of inflammation,
TGF- 1 has a known capacity to induce collagen and fi-
bronectin synthesis and thus to promote fibrosis. In con-
trast, IL-10 has been shown to inhibit collagen synthesis
and prevent fibrosis (44, 45), not only that caused by TGF-
 1, but also by TNF-  (46, 47) and IL-13 (14). On this
basis we explored the possibility that the fibrogenic proper-
ties of TGF- 1 can be brought under control by IL-10 co-
secretion. In these studies we showed that intranasal ad-
ministration of pTet-On-TGF- 1 did not induce fibrosis
of the lung, the organ most exposed to TGF- 1 as a result
of intranasal plasmid administration. In contrast, such ad-
ministration prevented bleomycin-induced pulmonary fi-
brosis, a fibrosis that is at least in part mediated by endoge-
nous TGF-   production (27, 48). That this seemingly
paradoxical effect was due to the cosecretion of IL-10 was
shown by the fact that TGF- 1 plasmid administration did
not prevent bleomycin-induced fibrosis in IL-10–deficient
mice (in whom IL-10 cosecretion cannot occur). These
findings strongly suggest that the IL-10 antifibrotic effect is
dominant over the TGF- 1 profibrotic effect, even in the
face of endogenous (nonlymphoid origin) TGF-  produc-
tion and that IL-10 protects the animal from TGF- 1–
mediated fibrosis. By extension, they suggest that induc-
tion of TGF- 1–secreting cells by administration of a
plasmid such as pTet-On-TGF- 1 that leads to super-
physiologic IL-10 secretion may have an unexpected anti-
fibrotic effect that bodes well for its use as a therapy for
autoimmune diseases.
We thank Sara Kaul for preparing this manuscript. We also thank
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